Background: When indicated, guidelines recommend measurement of lipoprotein(a) for cardiovascular risk assessment. However, temporal variability in lipoprotein(a) is not well understood, and it is unclear if repeat testing may help refine risk prediction of coronary artery disease (CAD).
Objectives: The authors examined the stability of repeat lipoprotein(a) measurements and the association between instability in lipoprotein(a) molar concentration with incident CAD.
Methods: The authors assessed the correlation between baseline and first follow-up measurements of lipoprotein(a) in the UK Biobank (n = 16,017 unrelated individuals). The association between change in lipoprotein(a) molar concentration and incident CAD was assessed among 15,432 participants using Cox proportional hazards models.
Results: Baseline and follow-up lipoprotein(a) molar concentration were significantly correlated over a median of 4.42 years (IQR: 3.69-4.93 years; Spearman rho = 0.96; P < 0.0001). The correlation between baseline and follow-up lipoprotein(a) molar concentration were stable across time between measurements of <3 (rho = 0.96), 3-4 (rho = 0.97), 4-5 (rho = 0.96), and >5 years (rho = 0.96). Although there were negligible-to-modest associations between statin use and changes in lipoprotein(a) molar concentration, statin usage was associated with a significant increase in lipoprotein(a) among individuals with baseline levels ≥70 nmol/L. Follow-up lipoprotein(a) molar concentration was significantly associated with risk of incident CAD (HR per 120 nmol/L: 1.32 [95% CI: 1.16-1.50]; P = 0.0002). However, the delta between follow-up and baseline lipoprotein(a) molar concentration was not significantly associated with incident CAD independent of follow-up lipoprotein(a) (P = 0.98).
Conclusions: These findings suggest that, in the absence of therapies substantially altering lipoprotein(a), a single accurate measurement of lipoprotein(a) molar concentration is an efficient method to inform CAD risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863206 | PMC |
| http://dx.doi.org/10.1016/j.jacc.2021.11.055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.
JAMA
November 2024
Eli Lilly and Company, Indianapolis, Indiana.
Article Synopsis
- A recent study showed that muvalaplin effectively inhibits the formation of lipoprotein(a), reducing its levels significantly, with reductions up to 85.8% observed in higher dosages over a 12-week period for those at high cardiovascular risk.
- * The phase 2 trial involved 233 participants with elevated lipoprotein(a) and conditions like atherosclerosis and diabetes, testing different dosages of muvalaplin against a placebo.
- * Results indicated substantial decreases in lipoprotein(a) concentrations and generally demonstrated that muvalaplin is well tolerated, but the long-term effects on high-risk populations require further investigation.
Strategies to verify equimolar peptide release in mass spectrometry-based protein quantification exemplified for apolipoprotein(a).
Clin Chem Lab Med
October 2024
Department of Clinical Chemistry and Laboratory Medicine, 4501 Leiden University Medical Center, Leiden, The Netherlands.
Objectives: Quantitative protein mass spectrometry (MS) is ideally suited for precision diagnostics and for reference standardization of protein analytes. At the Leiden Apolipoprotein Reference Laboratory we apply MS strategies to obtain detailed insight into the protein-to-peptide conversion in order to verify that quantifier peptides are not partly concealed in miscleaved protein backbone.
Methods: Apolipoprotein(a) (apo(a)) was digested in a non-optimal manner to enhance the number of miscleaved peptides that were identified by high resolution liquid chromatography tandem-MS measurements.
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
Eur J Prev Cardiol
August 2024
Division of Cardiology, University of Colorado School of Medicine, Box B130, Aurora, CO 80045, USA.
An LC-MS-based designated comparison method with similar performance to the Lp(a) reference measurement procedure to guide molar Lp(a) standardization.
Clin Proteomics
January 2024
Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Postzone E2-P, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background: The 2022 consensus statement of the European Atherosclerosis Society (EAS) on lipoprotein(a) (Lp(a)) recognizes the role of Lp(a) as a relevant genetically determined risk factor and recommends its measurement at least once in an individual's lifetime. It also strongly urges that Lp(a) test results are expressed as apolipoprotein (a) (apo(a)) amount of substance in molar units and no longer in confounded Lp(a) mass units (mg/dL or mg/L). Therefore, IVD manufacturers should transition to molar units.
View Article and Find Full Text PDFRelating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
January 2024
Division of Cardiology, University of Colorado School of Medicine, Aurora (M. Szarek, G.G.S.).
Article Synopsis
- - Lipoprotein(a) is known to increase cardiovascular risk and affects how patients benefit from PCSK9 inhibitors like alirocumab, but it's unclear how different testing methods for lipoprotein(a) correlate with cardiovascular events.
- - The ODYSSEY OUTCOMES trial analyzed patients with recent acute coronary syndrome, comparing the risks of major adverse cardiovascular events (MACE) between a placebo group and those treated with alirocumab, based on lipoprotein(a) levels measured by various assays.
- - Among 11,970 participants, different assays showed varying baseline lipoprotein(a) concentrations, with the highest correlation found between certain methods; additional analysis highlighted how lipoprotein(a) levels influenced MACE
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!